Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
24 valent pneumococcal conjugate vaccine · 2 trials · 1 indication
Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain within 7 days of vaccination
Percentage of participants with at least one Treatment Emergent Adverse Event (unsolicited AEs and SAEs)
Percentage of participants with serious adverse events (SAEs) and new onset of chronic illness (NOCIs)
Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain
Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination.
Percentage of participants with SAEs and NOCIs
| Arm | Type | Description |
|---|---|---|
| VAX-24 Low Dose | EXPERIMENTAL | Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1. |
| VAX-24 Mid Dose | EXPERIMENTAL | Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1. |
| VAX-24 Mixed Dose | EXPERIMENTAL | Participants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1. |
| PCV20 | ACTIVE_COMPARATOR | Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1. |
| Name | Type | Description |
|---|---|---|
| 24-Valent Pneumococcal Conjugate Vaccine | BIOLOGICAL | 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 |
| Pneumococcal 20-valent Conjugate Vaccine | BIOLOGICAL | 0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1 |
| 24 valent pneumococcal conjugate vaccine | BIOLOGICAL | 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 |
| 20 valent pneumococcal conjugate vaccine | BIOLOGICAL | 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1 |
Inclusion Criteria: * Male or female age 65 or older. * Able and willing to complete the informed consent process. * Available for clinical follow-up through the last study visit at 6 months after the study vaccination. * In good general health as determined by medical history, vital signs, physica...
The 24 valent pneumococcal conjugate vaccine, also known as VAX-24, is used for pneumococcal vaccines, targeting prevention of pneumococcal disease. It is being developed by Vaxcyte, Inc. (PCVX) and is currently in Phase 2 clinical development.
The 24 valent pneumococcal conjugate vaccine targets pneumococcal bacteria by including 24 valent components to elicit an immune response against pneumococcal infections. It is designed to provide broad coverage against multiple serotypes of Streptococcus pneumoniae.
The 24 valent pneumococcal conjugate vaccine is developed by Vaxcyte, Inc., a biopharmaceutical company traded under the ticker PCVX. The vaccine is currently in clinical development for pneumococcal vaccines.
The 24 valent pneumococcal conjugate vaccine is in Phase 2 clinical development. It has completed two clinical trials, including a Phase 1 study and a Phase 2 study, with a total enrollment of 1042 participants.
The 24 valent pneumococcal conjugate vaccine has completed two clinical trials: NCT05266456, a Phase 1 study in adults with 835 participants, and NCT05297578, a Phase 2 study in older adults with 207 participants. Both trials were conducted in the United States.
Yes, the 24 valent pneumococcal conjugate vaccine is also known as VAX-24. It is an investigational vaccine being developed by Vaxcyte, Inc. for pneumococcal vaccines, currently in Phase 2 clinical development.